Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA
Intercure Ltd. Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.	Israel	INCR
Intercure Ltd. A leading producer of pharmaceutical-grade, GMP-certified medical cannabis products.	United States of America	INCR
Intervacc AB Develops recombinant protein vaccines and diagnostics for animal health, like Strangvac® for horses.	Sweden	IVACC
iNtRON Biotechnology, Inc. Develops phage therapeutics and molecular diagnostics to combat infectious diseases.	South Korea	048530
Inventage Lab Inc. Develops drug delivery systems using microfluidics for chronic diseases and gene therapies.	South Korea	389470
Inventiva S.A. Develops oral small molecule therapies for NASH, fibrosis, and rare metabolic disorders.	United States of America	IVA
Invivyd, Inc. Develops evolution-resistant antibodies to protect against viral diseases like COVID-19 and flu.	United States of America	IVVD
IO Biotech, Inc. Develops dual-action, off-the-shelf therapeutic cancer vaccines for solid tumors.	United States of America	IOBT
IONIS PHARMACEUTICALS INC A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.	United States of America	IONS